Full Text View
Tabular View
Study Results
Related Studies
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
This study has been completed.
Study NCT00467649   Information provided by Amylin Pharmaceuticals, Inc.
First Received: April 27, 2007   Last Updated: April 10, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Type 2 Diabetes Mellitus
Additional conditions recognized in this trial
Diabetes Mellitus
Diabetes Mellitus, Type 2
More general conditions related to this trial
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
pramlintide acetate
Additional drug interventions recognized in this trial
Glargine
Insulin
Insulin glulisine
Insulin LISPRO
Insulin, Asp(B28)-
Pramlintide
More general drug interventions related to this trial
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Amylin Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services